374 related articles for article (PubMed ID: 27795938)
21. Multiparametric MRI in Patients With Nonalcoholic Fatty Liver Disease.
Schaapman JJ; Tushuizen ME; Coenraad MJ; Lamb HJ
J Magn Reson Imaging; 2021 Jun; 53(6):1623-1631. PubMed ID: 32822095
[TBL] [Abstract][Full Text] [Related]
22. MR elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease.
Costa-Silva L; Ferolla SM; Lima AS; Vidigal PVT; Ferrari TCA
Eur J Radiol; 2018 Jan; 98():82-89. PubMed ID: 29279175
[TBL] [Abstract][Full Text] [Related]
23. Association Between Magnetic Resonance Imaging-Proton Density Fat Fraction and Liver Histology Features in Patients With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis.
Wildman-Tobriner B; Middleton MM; Moylan CA; Rossi S; Flores O; Chang ZA; Abdelmalek MF; Sirlin CB; Bashir MR
Gastroenterology; 2018 Nov; 155(5):1428-1435.e2. PubMed ID: 30031769
[TBL] [Abstract][Full Text] [Related]
24. Hepatic Alanine Differentiates Nonalcoholic Steatohepatitis From Simple Steatosis in Humans and Mice: A Proton MR Spectroscopy Study With Long Echo Time.
Kim TH; Jun HY; Kim KJ; Lee YH; Lee MS; Choi KH; Yun KJ; Jeong YY; Jun CH; Cho EY; Yoon KH
J Magn Reson Imaging; 2017 Nov; 46(5):1298-1310. PubMed ID: 28225569
[TBL] [Abstract][Full Text] [Related]
25. The role of noninvasive tests and liver biopsy in the diagnosis of nonalcoholic fatty liver disease.
Isabela Andronescu C; Roxana Purcarea M; Aurel Babes P
J Med Life; 2018; 11(3):243-246. PubMed ID: 30364513
[TBL] [Abstract][Full Text] [Related]
26. [An interpretation of the AASLD practice guideline on the diagnosis and management of nonalcoholic fatty liver disease in 2017].
Nan YM; Fu N; Li WC; Kong LL; Yuan XW; Zhang SY; Liu LD; Lu Y; Cui LY
Zhonghua Gan Zang Bing Za Zhi; 2017 Sep; 25(9):687-694. PubMed ID: 29108191
[TBL] [Abstract][Full Text] [Related]
27. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease.
Staufer K; Halilbasic E; Spindelboeck W; Eilenberg M; Prager G; Stadlbauer V; Posch A; Munda P; Marculescu R; Obermayer-Pietsch B; Stift J; Lackner C; Trauner M; Stauber RE
United European Gastroenterol J; 2019 Oct; 7(8):1113-1123. PubMed ID: 31662868
[TBL] [Abstract][Full Text] [Related]
28. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.
Dharmalingam M; Yamasandhi PG
Indian J Endocrinol Metab; 2018; 22(3):421-428. PubMed ID: 30090738
[TBL] [Abstract][Full Text] [Related]
29. Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease.
Tanwar S; Trembling PM; Guha IN; Parkes J; Kaye P; Burt AD; Ryder SD; Aithal GP; Day CP; Rosenberg WM
Hepatology; 2013 Jan; 57(1):103-11. PubMed ID: 22930399
[TBL] [Abstract][Full Text] [Related]
30. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
[TBL] [Abstract][Full Text] [Related]
31. Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD.
Pearce SG; Thosani NC; Pan JJ
Biomark Res; 2013 Feb; 1(1):7. PubMed ID: 24252302
[TBL] [Abstract][Full Text] [Related]
32. Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease.
Lee DH
Endocrinol Metab (Seoul); 2020 Jun; 35(2):243-259. PubMed ID: 32615709
[TBL] [Abstract][Full Text] [Related]
33. Liver fibrosis markers of nonalcoholic steatohepatitis.
Enomoto H; Bando Y; Nakamura H; Nishiguchi S; Koga M
World J Gastroenterol; 2015 Jun; 21(24):7427-35. PubMed ID: 26139988
[TBL] [Abstract][Full Text] [Related]
34. Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials.
Caussy C; Reeder SB; Sirlin CB; Loomba R
Hepatology; 2018 Aug; 68(2):763-772. PubMed ID: 29356032
[TBL] [Abstract][Full Text] [Related]
35. Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease.
Castera L
Semin Liver Dis; 2015 Aug; 35(3):291-303. PubMed ID: 26378645
[TBL] [Abstract][Full Text] [Related]
36. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
[TBL] [Abstract][Full Text] [Related]
37. [New advances in diagnosis of nonalcoholic fatty liver disease].
Qu Y; Lu L
Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):85-8. PubMed ID: 26983472
[TBL] [Abstract][Full Text] [Related]
38. The Role of Long Non-Coding RNAs (lncRNAs) in the Development and Progression of Fibrosis Associated with Nonalcoholic Fatty Liver Disease (NAFLD).
Hanson A; Wilhelmsen D; DiStefano JK
Noncoding RNA; 2018 Aug; 4(3):. PubMed ID: 30134610
[TBL] [Abstract][Full Text] [Related]
39. Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness.
Liebig S; Stoeckmann N; Geier A; Rau M; Schattenberg JM; Bahr MJ; Manns MP; Jaeckel E; Schulze-Osthoff K; Bantel H
Clin Transl Gastroenterol; 2019 Aug; 10(8):e00066. PubMed ID: 31397685
[TBL] [Abstract][Full Text] [Related]
40. Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients With Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis.
Arulanandan A; Ang B; Bettencourt R; Hooker J; Behling C; Lin GY; Valasek MA; Ix JH; Schnabl B; Sirlin CB; Loomba R
Clin Gastroenterol Hepatol; 2015 Aug; 13(8):1513-20.e1. PubMed ID: 25661453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]